Does poly-N-acetyl glucosamine patch use reduce arteriovenous fistula and graft failure rates in hemodialysis patients with end-stage renal disease?

American Journal of the Medical Sciences

Volumn 338, Issue 3, 2009, Pages 178-184

  Ünalp, Aynur ^a   Ploth, David W ^b   Colvin, Ryan ^a   Counts, Caroline ^b   Shepp, Pamela H ^b   Van Natta, Mark L ^a   Meinert, Curtis L ^a  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Arteriovenous fistula; Arteriovenous graft; End stage renal disease (ESRD); Hemodialysis; Poly N acetyl glucosamine (p GlcNAc) fiber

Indexed keywords

N ACETYLGLUCOSAMINE; WARFARIN; POLY N ACETYL GLUCOSAMINE; POLY-N-ACETYL GLUCOSAMINE;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ARTERIOVENOUS FISTULA; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG USE; FEMALE; GRAFT FAILURE; HEMODIALYSIS; HUMAN; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; OUTPATIENT CARE; TREATMENT FAILURE; TREATMENT OUTCOME; VASCULAR ACCESS; CHRONIC KIDNEY FAILURE; GRAFT REJECTION; HEMOSTASIS; KIDNEY TRANSPLANTATION; METHODOLOGY; MIDDLE AGED; RENAL REPLACEMENT THERAPY;

ACETYLGLUCOSAMINE; FEMALE; GRAFT REJECTION; HEMOSTASIS; HUMANS; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; RENAL DIALYSIS;

EID: 70349248617     PISSN: 00029629     EISSN: None     Source Type: Journal    
DOI: 10.1097/MAJ.0b013e3181abf66b     Document Type: Article

References (31)

1. U.S. Renal Data System: USRDS 2006 Annual data report: atlas of end-stage renal disease in the United States. Bethesda (MD): National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2006.
2. Palder SB, Kirkman RL, Whittemore AD, et al. Vascular access for hemodialysis: patency rates and results of revision. Ann Surg 1985; 202:235-239
3. Raju S. PTFE grafts for hemodialysis access: techniques for insertion and management of complications. Ann Surg 1987;206:666-673 (Pubitemid 18012149)
4. Munda R, First R, Alexander JW, et al. Polytetrafluoroethylene graft survival in hemodialysis. JAMA 1983;249:219-222
5. Schuman E, Quinn S, Standage B, et al. Thrombolysis versus thrombectomy for occluded hemodialysis grafts. Am J Surg 1994;167:473-476 (Pubitemid 24203526)
6. National Kidney Foundation: DOQI clinical practice guidelines for vascular access. Am J Kidney Dis 1997;30(suppl 3):S154-96.
7. Schwab SJ. Vascular access for hemodialysis. Kidney Int 1999;55: 2078-2090
8. National Kidney Foundation: K/DOQI clinical practice guidelines for vascular access: update 2000. Am J Kidney Dis 2001;37(suppl 1): S137-81.
9. Gibson KD, Gillen DL, Caps MT, et al. Vascular access survival and incidence of revisions: a comparison of prosthetic grafts, simple autogenous fistulas, and venous transposition fistulas from the United States Renal Data System Dialysis Morbidity and Mortality Study. J Vasc Surg 2001;34:694-700.
10. National Kidney Foundation: NKF-K/DOQI clinical practice guidelines for vascular access: update 2006. Am J Kidney Dis 2006; 48(suppl 1):S176-276.
11. Roy-Chaudhury P, Sukhatme VP, Cheung AK. Hemodialysis vascular access dysfunction: a cellular and molecular viewpoint. J Am Soc Nephol 2006;17:1112-1127
12. Berkoben M, Schwab SJ. Maintenance of permanent hemodialysis vascular access patency. ANNA J 1995;22:17-24.
13. Vournakis JN, Demcheva M, Whitson A, et al. Isolation, purification, and characterization of poly-N-acetyl glucosamine use as a hemostatic agent. J Trauma 2004;57:S2-6. (Pubitemid 39079210)
14. Cole DJ, Connolly RJ, Chan MW, et al. A pilot study evaluating the efficacy of a fully acetylated poly-N-acetyl glucosamine membrane formulation as a topical hemostatic agent. Surgery 1999;126:510-517
15. Vournakis JN, Demcheva M, Whitson AB, et al. The RDH bandage: hemostasis and survival in a lethal aortotomy hemorrhage model. J Surg Res 2003;113:1-5. (Pubitemid 36999785)
16. Najjar SF, Healey NA, Healey CM, et al. Evaluation of poly-N-acetyl glucosamine as a hemostatic agent in patients undergoing cardiac catheterization: a double-blind, randomized study. J Trauma 2004;57: S38-41.
17. Jewelewicz DD, Cohn SM, Crookes BA, et al. Modified rapid deployment hemostat bandage reduces blood loss and mortality in coagulopathic pigs with severe liver injury. J Trauma 2004;55:275-280
18. King DR, Cohn SM, Proctor KG. Modified rapid deployment hemostat bandage terminates bleeding in coagulopathic patients with severe visceral injuries. J Trauma 2004;57:756-759
19. Nader RG, Garcia JC, Drushal K, et al. Clinical evaluation of SyvekPatch in patients undergoing interventional, EPS and diagnostic cardiac catheterization procedures. J Invasive Cardiol 2002;14:305-307 (Pubitemid 34651237)
20. Fischer TH, Bode AP, Demcheva M, et al. Hemostatic properties of glucosamine-based materials. J Biomed Mater Res 2007;80A:167-174
21. Ikeda Y, Young LH, Vournakis JN, et al. Vascular effects of poly-N-acetylglucosamine in isolated rat aortic rings. J Surg Res 2002; 102:215-220 (Pubitemid 34969470)
22. Fischer TH, Thatte HS, Nichols TC, et al. Synergistic platelet integrin signaling and factor XII activation in poly-N-acetyl glucosamine fiber mediated hemostasis. Biomaterials 2005;26:5433-5443
23. Fischer TH, Valeri CR, Smith CJ, et al. Non-classical processes in surface hemostasis: mechanisms for the poly-N-acetyl glucosamineinduced alteration of red blood cell morphology and prothrombogenicity. Biomed Mater 2008;3:15009.
24. Meyer KB, Jenuleson CS, Vital A, et al. Control of post dialysis bleeding in patients on chronic oral anticoagulation therapy. J Am Soc Nephrol 1999;10:212A.
25. Vournakis JN, Eldridge J, Demcheva M, et al. Poly-N-acetyl glucosamine nanofibers regulate endothelial cell movement and angiogenesis: dependency on integrin activation of Ets1. J Vasc Res 2008;45: 222-232 (Pubitemid 351543146)
26. Pietramaggiori G, Yang H, Scherer SS, et al. Effects of poly-N-acetyl glucosamine (pGlcNAc) patch on wound healing in db/db mouse. J Trauma 2008;64:803-808
27. Stata Statistical Software: Release 9. College Station (TX): Stata Corporation; 2007.
28. McCullagh P, Nelder JA. Generalized linear models, 2nd ed. London: Chapman and Hall; 1989.
29. Liang KY, Zeger SL. Longitudinal data analysis using generalized linear models. Biometrika 1986;73:13-22.
30. Abularrage CJ, Sidawy AN, Weiswasser JM, et al. Medical factors affecting patency of arteriovenous access. Semin Vasc Surg 2004;17: 25-31.
31. Saran R, Dykstra DM, Wolfe RA, et al. Association between vascular access failure and the use of specific drugs: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 2002;40:1255-1263 (Pubitemid 35403138)